BioSpace News Archive

Crescita Therapeutics Inc., a Canadian commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, reported its financial results for the third quarter ended September 30, 2019.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, posted a narrated overview of its next-generation amyloid-beta (Aβ)-targeting drug candidate, PMN310 for Alzheimer’s disease (AD), juxtaposed with Biogen’s first-generation candidate, aducanumab.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, have entered a preclinical research collaboration to explore the potential combinatory effect of their platform-based immunotherapies.

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically meaningful results from its recently completed two Phase 2b studies of its lead drug candidate, Nyxol Eye Drops.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2019 and provided a corporate update.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after the market close on Thursday, November 14, 2019.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present at the Society for the Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in National Harbor, MD.

Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders.

IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2019..

CorMedix Inc. announced that it will report its financial results for the third quarter and nine months ended September 30, 2019, after the market close on Thursday, November 14 and will host a corporate update conference call at 4:30pm Eastern Time.